Iliofemoral endarterectomy and stenting improves mid-term patency for advanced aortoiliac disease with concomitant common femoral disease
Vascular · 2025
DOI: 10.1177/17085381251377294 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Vascular, 2025. Verfasst von Nathan J Reinert und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Vascular Patency, Femoral Artery, Stents, Iliac Artery. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective
Combined iliofemoral endarterectomy and iliac stenting (IFE + S) is a proven surgical approach for TransAtlantic Inter-society Consensus (TASC) C and D aortoiliac occlusive disease (AIOD). Iliac stenting alone (ISA) may be an attractive, minimally invasive option in select cases; however, untreated moderate-to-severe common femoral disease may threaten iliac stent patency and limit symptom improvement. This study evaluates the mid-term patency rates after IFE + S versus ISA for TASC C and D AIOD as well as the rate of interval femoral endarterectomies in those who underwent ISA.
Methods
This is a retrospective, single-center analysis of patients from 2011 to 2018 with TASC C or D AIOD and concomitant femoral artery stenosis of >50% who underwent IFE + S or ISA. Baseline lesion and patient characteristics such as TASC classification, degree of stenosis, calcification severity, lesion length, and baseline ankle-brachial index (ABI) were collected. Primary, primary-assisted, and secondary patency rates were calculated over three years with Kaplan-Meier estimates. The rate of interval femoral endarterectomies in the ISA cohort was measured at the same time endpoint.
Results
Of the 78 limbs identified, 64 (82.1%) underwent IFE + S and 14 (17.9%) underwent ISA. No significant differences in aortoiliac or femoral lesion characteristics existed. Iliac stent primary patency was significantly improved in the IFE + S group at three years [85.1% versus 55.6%, HR 3.96 (95% CI 1.54, 10.2, p = .004)]. Primary-assisted and secondary patency rates were not significantly different. Five (35.7%) patients in the ISA cohort required an interval femoral endarterectomy for ischemic symptoms over the three-year endpoint.
Conclusions
In select patient populations with concomitant TASC C or D AIOD and common femoral artery disease, IFE + S may provide improved mid-term primary stent patency when compared to ISA. A subset of patients who undergo ISA may require future femoral endarterectomies for ischemic symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Vascular Surgery, Heart Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Vascular Surgery, Heart and Vascular Surgery Institute,Bridgeport Hospital, Bridgeport, CT, USA.
ORCID-Profile: Nathan J Reinert, Ali Khalifeh
Zitieren
APA
Reinert, N. J., Caputo, F. J., Ahuja, N., Alexander, A., Bena, J., Smith, A., Khalifeh, A., Hanak, C., Ambani, R., Hoell, N. G., Kirksey, L., Lyden, S. P., & Quatromoni, J. G. (2025). Iliofemoral endarterectomy and stenting improves mid-term patency for advanced aortoiliac disease with concomitant common femoral disease. Vascular. https://doi.org/10.1177/17085381251377294
Vancouver
Reinert NJ, Caputo FJ, Ahuja N, Alexander A, Bena J, Smith A, et al. Iliofemoral endarterectomy and stenting improves mid-term patency for advanced aortoiliac disease with concomitant common femoral disease. Vascular. 2025. doi:10.1177/17085381251377294
BibTeX
@article{Reinert2025,
author = {Reinert, Nathan J and Caputo, Francis J and Ahuja, Natasha and Alexander, Alice and Bena, James and Smith, Andrew and Khalifeh, Ali and Hanak, Courtney and Ambani, Ravi and Hoell, Nicholas G and Kirksey, Levester and Lyden, Sean P and Quatromoni, Jon G},
title = {Iliofemoral endarterectomy and stenting improves mid-term patency for advanced aortoiliac disease with concomitant common femoral disease},
journal = {Vascular},
year = {2025},
doi = {10.1177/17085381251377294}
}
EUVIMED